About Medac Pharma
Medac Pharma is a Healthcare company based in Chicago (United States) founded in 2012, and was acquired by Medexus Pharmaceuticals in October 2018. Therapeutics for autoimmune diseases and cancer are developed. Medac Pharma offers products and services including Trecondyv, GRAFAPEX, and Gleolan. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is Medexus Pharmaceuticals, Inc. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Medac Pharma was founded in 2012 and is headquartered in Chicago, United States. Focus is placed on the pharmaceutical sector, where therapeutics for autoimmune diseases and cancer are developed. Operations center on a product pipeline that includes Rasuvo, a methotrexate injection in the launch stage, alongside MPI-3501 for oncology, MPI-2710 for hematology, MPI-2720 for hematology, and MPI-2730 for hematology, all in Phase 1II clinical trials.
- Headquarters Chicago, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website medacpharma.com
- Social LinkedIn
- Acquired by Medexus Pharmaceuticals (Oct 2018)
- Legal Name Medexus Pharmaceuticals, Inc.
- Investors
- Acquired byMedexus Pharmaceuticals
(Oct 2018)
Products & Services of Medac Pharma
Medac Pharma offers a comprehensive portfolio of products and services, including Trecondyv, GRAFAPEX, and Gleolan.
Treats rare diseases through injection for patient care.
Provides treatment for specific rare disease conditions.
Supports oncology treatments for rare disease applications.
Investors in Medac Pharma
Medac Pharma has secured backing from 1 investor. Prominent investors backing the company include Medexus Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured for rheumatology, immunology, and oncology sectors. | 2004 | medexus.com | Montreal, Canada |
Investor details for Medac Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Medac Pharma
2 dated milestones of Medac Pharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Medac Pharma is founded.
- Exit Acquired by Medexus Pharmaceuticals.
Competitors of Medac Pharma
Medac Pharma has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Medac Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Medac Pharma
Websites that share an audience with Medac Pharma (medacpharma.com).
Websites whose visitors overlap most with Medac Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medac.de | 26% | 9.9K | #2,631,650 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Medac Pharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medac Pharma
Complete news archive for Medac Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medac Pharma
Medac Pharma was founded in 2012.
Medac Pharma is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Medac Pharma was founded in 2012 and is headquartered in Chicago, United States. Focus is placed on the pharmaceutical sector, where therapeutics for autoimmune diseases and cancer are developed. Operations center on a product pipeline that includes Rasuvo, a methotrexate injection in the launch stage, alongside MPI-3501 for oncology, MPI-2710 for hematology, MPI-2720 for hematology, and MPI-2730 for hematology, all in Phase 1II clinical trials.
Medac Pharma's top competitors include Kymeratx, PureTech Health and Biogen.
Medac Pharma offers Trecondyv, GRAFAPEX, and Gleolan.
Medac Pharma has 1 investor. Key investors include Medexus Pharmaceuticals.
Medac Pharma operates through Medexus Pharmaceuticals, Inc..
Yes. Medac Pharma was acquired by Medexus Pharmaceuticals in October 2018.